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by Elsevier B.V. This is an open accesAbstract Background and objectives: IL-31 appears to be an important regulator of Th2 re-
sponses and was found to be present in patients with atopic dermatitis. This study was con-
ducted to compare IL-31 serum levels in allergic rhinitis (AR) patients and normal controls
and to determine IL-31 serum levels according to AR severity.
Patients and methods: Across-sectional studywasconductedwithARpatientswhomettheAllergic
Rhinitis and its Impact on Asthma (ARIA) classification criteria for AR. Normal control subjects were
recruited from local healthy people in HUSM. The severity of AR was assessed using ARIA. Fiveml of
blood were drawn from each subject. The serum samples were analyzed for IL-31 using ELISA kits.
Results: The results showed that IL-31 serum level was higher in allergic rhinitis patients (mean (SD)
4107.70 (16961.51)) than in normal controls (2195.55 (9016.57)); however, this difference was not
statistically significant,withapvalueof0.406determinedbyan independent-T test.Theresultsalso
showed no significant difference in IL-31 levels according to AR severity, with a p value of 0.245
determined by a ManneWhitney test.
Conclusion: There was no significant difference in IL-31 serum levels between normal controls and
ARpatients or betweenpatientswith different AR severities. Future studieswith larger sample sizes
should be performed.
Copyright ª 2014, King Faisal Specialist Hospital & Research Centre (General Organization), Saudi
Arabia. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).of Immunology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan,
(N.S. Mohd Ashari), syu_amin@yahoo.com (S.N. Syuhada Mohd Amin), wzuraida@usm.my (W.Z. Wan
. Musa), azriani@usm.my (A.A. Rahman), irfankb@usm.my (I. Mohamad).
f King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.
14.10.003
al Specialist Hospital & Research Centre (General Organization), Saudi Arabia. Production and hosting
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
70 N.S. Mohd Ashari et al.1. IntroductionTable 1 Classification of patients’ allergic rhinitis
severity.
Classification Symptoms
Mild Normal sleep, normal daily activities,
normal work and school activities,
no troublesome symptoms
Moderate
to severe
Abnormal sleep; impairment of daily
activities, sports and leisure;
problems at work or school and
troublesome symptomsAn allergy is a tendency to immunologically respond to a
common, naturally occurring ingested or inhaled allergen
by continually producing immunoglobulin E (Ig E) anti-
bodies. Immune responses are controlled by cytokines.
Interleukin 31 (IL-31) is a cytokine that contains four helical
bundle cytokines [1] and belongs to family that includes IL-
6, IL-11 and IL-27. IL-31 appears to be an important regu-
lator of T-helper 2 (Th2) responses.
IL-31 stimulates the secretion of proinflammatory cyto-
kines, chemokines and matrix metalloproteinases (MMPs)
[2,3]. IL-31 may function as a proinflammatory cytokine in
the recruitment of polymorphonuclear cells, monocytes
and T cells.
The most common clinical disease involving environ-
mental exposure to allergens is allergic rhinitis (AR) fol-
lowed by atopic dermatitis (AD) and atopic asthma (AA) [2].
IL-31 serum levels are significantly higher in AD patients
than in healthy individuals [4]. The association between IL-
31 levels and AR is not well described in the literature.
Thus, this study was conducted to demonstrate the levels of
IL-31 in a local population in Malaysia. We compared IL-31
levels between AR patients and normal controls and be-
tween patients with AR of differing severity.
2. Patients and methods
2.1. Study subjects
A comparative cross-sectional study was conducted in 2011
and included patients with allergic rhinitis who met the
Allergic Rhinitis and its Impact on Asthma (ARIA) classifi-
cation criteria for AR. The patients were enrolled from the
Otorhinolaryngology-Head & Neck Surgery (ORL-HNS) clinic
at the Hospital Universiti Sains Malaysia (HUSM). To be
included, the patients could not have received any systemic
treatment for two months prior to the study. Normal con-
trol subjects were recruited from local healthy people at
the HUSM who did not have any history or symptoms of AR.
The sample size was calculated using PS software, Dupport
and Plummer, 1997. Based on the t-test, 70 patients with
AR and 70 normal control subjects were included in this
study. After written informed consent was obtained, clin-
ical profiles were recorded. Five ml of blood were drawn
from each subject into plain tubes. The severity of AR was
assessed using the ARIA criteria (Table 1).
2.2. Obtaining the serum
The blood samples were left to clot for 1e3 h after being
drawn. Then they were centrifuged (Centrifuge 5810 R) for
5 min at 2000 rpm (rotation per minute). The serum then
was stored at 80 C (degree Celsius).
2.3. ELISA
IL-31 was detected using a commercially available ELISA kit
(R&D System). The test was performed according to themanufacturer’s protocol. Based on our standard curves, the
detection limit was approximately 50 pg/ml.2.4. Plate preparation
Each well of a 96-well microplate was immediately coated
with 100 mL of the unlabeled monoclonal antibody specific
for human IL-31. Then, the plate was sealed, and it was
incubated overnight at room temperature. Each well was
aspirated and washed with wash buffer. The process was
repeated two times for a total of three washes. Then,
300 mL of reagent diluents were added to each well to block
the plates. The plate was incubated at room temperature
for a minimum of 1 h. The wash was repeated as in the
previous washing step, after which the plate was ready for
sample addition.2.5. Assay procedure
One hundred microliters of a sample or a standard in re-
agent diluents was added per well. After sample addition,
the plate was incubated for 2 h at room temperature. Then,
the wash was repeated as during plate preparation. One
hundred microliters of biotin-labeled anti-human IL-31
detection antibody was added to each well. Then, the
plate was incubated at room temperature for 2 h, and the
washing process was repeated. One hundred microliters of
horseradish peroxidase (HRP) labeled anti-biotin antibody
was added to each well. Then, the plate was incubated for
20 min, and the washing process was repeated.
After that, 100 mL of tetramethylbenzidine (TMB) sub-
strate solution was added to each well, and the plate was
incubated for 20 min at room temperature. Then, 50 mL of
stop solution was added to each well. Then, the color
development was quenched, and the intensity was
measured at 450 nm.2.6. Data entry and statistical analysis
The data entry and analysis were performed using Statis-
tical Package for Social Sciences (SPSS) version 20.0. IL-31
serum levels of AR patients and normal control subjects
were compared using the Independent-T test. IL-31 serum
levels according to severity of AR were compared using the
ManneWhitney test.
Table 2 Sociodemographic characteristics of respondents.
Allergic
rhinitis, n (%)
Normal
controls, n (%)
Race Malay 61 (87) 68 (96)
Chinese 8 (11) 1 (2)
Indian 0 (0) 1 (2)
Others 1 (2) 0 (0)
Age (years) <18 11 (16) 0 (0)
18e35 21 (30) 43 (61)
>35 38 (54) 27 (39)
Sex Male 30 (43) 35 (50)
Female 40 (57) 35 (50)
Table 4 IL-31 serum levels according to allergic rhinitis
severity.
Severity of AR n Median (IQR) IL-31
levels (pg/ml)
Z statistic p value
Mild 24 168.08 (637.24) 1.163 0.245
Moderateesevere 46 264.10 (1089.96)
Result was significant if p value < 0.05 by ManneWhitney test.
IL-31 in allergic rhinitis 713. Results
A total of 140 subjects (70 allergic rhinitis patients and 70
normal controls) were enrolled in the study. Of the 70
normal control subjects, 35 were male (50%) and 35 were
female (50%). Of the 70 allergic rhinitis subjects, 30 were
male (43%) and 40 were female (57%). The other socio-
demographic data of the subjects are shown in Table 2.
As shown in Table 3, there was no significant difference
in the IL-31 serum levels between AR patients and normal
control subjects. However, the mean (SD) IL-31 serum level
was higher for the AR patients than for the normal control
subjects.
Out of 70 AR patients, 24 were diagnosed with mild AR,
while the other 46 were diagnosed with moderateesevere
AR. No significant difference in the IL-31 serum levels ac-
cording to AR severity was found. The median (IQR) IL-31
serum level was higher in the moderateesevere AR subjects
than in the mild AR subjects, as shown in Table 4.
4. Discussion
Atopy is one’s propensity to produce IgE antibodies and
develop sensitization to environmental triggers [5]. In this
study, the results showed no significant differences in IL-31
levels between AR and normal control subjects; however,
we observed that the serum samples from the AR patients
had higher levels of IL-31 than those of the normal con-
trols. The findings of this study are similar to those of a
previous study in AD patients; that study demonstrated
higher levels of IL-31 in allergic patients than in healthy
controls [3]. However, the difference was not statistically
significant.
The AR patients in a study had AR of mild or moder-
ateesevere severity. However, the results showed noTable 3 IL-31 serum levels in normal control subjects and
allergic rhinitis patients.
Group n Mean (SD) pg/ml p value
Allergic rhinitis 70 4107.70 (16961.51) 0.406
Normal controls 70 2195.55 (9016.57)
Result was significant if p value < 0.05 by independent-T test.significant difference between IL-31 levels according to AR
severity. This may be due to the subjects being non-
normally distributed and to the limited sample size of this
study.
The majority of patients in the study sample were
female (Fig. 1). Gender is an important determinant of AR
occurrence and hospitalization. The effect of sex on AR
varies with age. However, it is not clear if the difference in
AR occurrence by sex remains similar throughout adult-
hood. In a previous study of AR in Malaysia, the majority of
the patients were diagnosed with moderateesevere AR
according to the ARIA classification criteria [6]. Similar
findings were noted in our study.
Although many studies reported the presence of IL-31 in
atopic dermatitis (AD) patients, the relationship between
IL-31 and AR is still unclear [2,7,8]. In vivo animal studies
have shown that IL-31 is closely related to dermatitis, AD
and non-atopic dermatitis [9]. IL-31 serum levels were
found to be significantly higher in patients with AD
compared to healthy subjects [10e12]. IL-31 is also higher
in allergic asthmatic patients than in healthy subjects [13].
Similarly, our study demonstrated that IL-31 was higher
in AR patients than in healthy control subjects, although
the difference was not statistically significant. This non-
significant difference in IL-31 serum level may be consid-
ered to be similar to results reported by other authors who
concluded that IL-31 has a unique and independent role in
the pathophysiology of allergic rhinitis [14].
Previous studies found that IL-31 is higher in AD patients
compared to normal controls; thus, a major weakness of
this study was that patients with AD were not excluded.
This is because of the high association between AR and
other allergic diseases, including AD (60e80%). Addition-
ally, although the patients did not receive any systemic
treatment for AR for at least two months prior to studyFigure 1 The gender involve in IL-31 measurement between
non allergic subjects and allergic rhinitis patients.
72 N.S. Mohd Ashari et al.enrollment, they were still permitted to use topical treat-
ments to reduce their AR symptoms; this is another weak-
ness of this study.
5. Conclusion
We found that IL-31 was higher in the serum of AR patients
than in healthy controls; however, this difference was not
statistically significant. This might be due to the small
sample size of the study. Future studies with larger sample
sizes should be performed.Conflict of Interest
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